Home / Market News / $BDRX
benzinga Corporate Catalyst Impact 65/100 ● neutral

Biodexa Pharmaceuticals Enrolls 100 Patients In Its Registrational Phase 3 Serenta Trial Of eRapa In Familial Adenomatous Polyposis; Trial Is Recruiting At 29 Clinical Sites In U.S., Canada And Europe And Is Expected To Be Initiated Shortly

Oct 13, 2026, 12:35 PM UTC · Primary ticker $BDRX

Biodexa Pharmaceuticals announced the enrollment of 100 patients in its registrational Phase 3 Serenta trial for eRapa in Familial Adenomatous Polyposis (FAP). This milestone indicates progress in a key clinical trial, which is a moderate positive for the company's long-term prospects.

Biodexa Pharmaceuticals announced a significant milestone in its registrational Phase 3 Serenta trial for eRapa, having enrolled 100 patients. This trial is crucial for the potential approval of eRapa for Familial Adenomatous Polyposis (FAP), a rare genetic disorder. The enrollment progress is a positive indicator for the company's development pipeline and could lead to future revenue streams if the trial is successful. For traders, this news suggests a moderate positive sentiment for BDRX in the short term, as it de-risks the clinical development process slightly. Long-term implications depend on the trial's outcomes, particularly the futility analysis and final results, which could significantly impact the company's valuation. The key opportunity lies in the potential for eRapa to address an unmet medical need in FAP.

$BDRX positive Progress in key clinical trial
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.